CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ran, Qian ^a   Hao, Ping ^a   Xiao, Yanni ^a   Xiang, Lixing ^a   Ye, Xingde ^a   Deng, Xiaojun ^a   Zhao, Jiang ^a   Li, Zhongjun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CR6 INTERACTING FACTOR 1; CYCLIN DEPENDENT KINASE 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW STROMAL CELL; CHILD; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IRON DEFICIENCY ANEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MALE; MIDDLE AGED; PRESCHOOL CHILD; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STROMA CELL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CELLULAR MICROENVIRONMENT; CHILD; CYCLIN-DEPENDENT KINASE 2; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTRACELLULAR SPACE; JURKAT CELLS; LEUKEMIA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; RNA, MESSENGER; YOUNG ADULT;

EID: 84895553125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085328     Document Type: Article

References (37)

1. Cornell RF, Palmer J (2012) Adult acute leukemia. Dis Mon 58: 219-238.
2. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, et al. (1990) Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323: 448-455. (Pubitemid 20231557)
3. Nair RR, Tolentino J, Hazlehurst LA (2010) The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 80: 602-612.
4. Correia AL, Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat.
5. Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, et al. (2012) Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. Leuk Res 36: 299-306.
6. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, et al. (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13: 6469-6478. (Pubitemid 350075037)
7. Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, et al. (2004) Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103: 2771-2778. (Pubitemid 38393036)
8. Lane SW, Scadden DT, Gilliland DG (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114: 1150-1157.
9. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, et al. (2010) Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 116: 1083-1091.
10. Vianello F, Villanova F, Tisato V, Lymperi S, Ho KK, et al. (2010) Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 95: 1081-1089.
11. Furuichi Y, Goi K, Inukai T, Sato H, Nemoto A, et al. (2007) Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res 67: 9852-9861. (Pubitemid 47621233)
12. Krause DS, Van Etten RA (2007) Right on target: eradicating leukemic stem cells. Trends Mol Med 13: 470-481. (Pubitemid 350086980)
13. Essers MA, Trumpp A (2010) Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 4: 443-450.
14. Jørgensen HG, Copland M, Allan EK, Jiang X, Eaves A, et al. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 12: 626-633. (Pubitemid 43166158)
15. Zhang B, Strauss AC, Chu S, Li M, Ho Y, et al. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17: 427-442.
16. Felipe Rico J, Hassane DC, Guzman ML (2012) Acute myelogenous leukemia stem cells: From Bench to Bedside. Cancer Lett.
17. Zhang X, Ran Q, Li Z, Liu Y, Liang X, et al. (2011) Cell cycle arrest of Jurkat cells by leukemic bone marrow stromal cells: possible mechanisms and involvement of CRIF1. Transplant Proc 43: 2770-2773.
18. Chung HK, Yi YW, Jung NC, Kim D, Suh JM, et al. (2003) CR6-interacting factor 1 interacts with Gadd45 family proteins and modulates the cell cycle. J Biol Chem 278: 28079-28088. (Pubitemid 36900005)
19. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, et al. (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453: 1072-1078. (Pubitemid 351871736)
20. Carroll WL, Raetz EA (2012) Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr 160: 10-18.
21. Hoelzer D, Gökbuget N (2012) Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 26: 25-32.
22. Fortney JE, Zhao W, Wenger SL, Gibson LF (2001) Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res 25: 901-907. (Pubitemid 32776581)
23. Kutner RH, Zhang XY, Reiser J (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4: 495-505.
24. Kim SJ, Kwon MC, Ryu MJ, Chung HK, Tadi S, et al. (2012) CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane. Cell Metab 16: 274-283.
25. Park KC, Song KH, Chung HK, Kim H, Kim DW, et al. (2005) CR6-interacting factor 1 interacts with orphan nuclear receptor Nur77 and inhibits its transactivation. Mol Endocrinol 19: 12-24. (Pubitemid 40065955)
26. Suh JH, Shong M, Choi HS, Lee K (2008) CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction. Mol Endocrinol 22: 33-46.
27. Kang HJ, Hong YB, Kim HJ, Bae I (2010) CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2 (NRF2) protein stability by proteasome-mediated degradation. J Biol Chem 285: 21258-21268.
28. Kwon MC, Koo BK, Kim YY, Lee SH, Kim NS, et al. (2009) Essential role of CR6-interacting factor 1 (Crif1) in E74-like factor 3 (ELF3)-mediated intestinal development. J Biol Chem 284: 33634-33641.
29. Kwon MC, Koo BK, Moon JS, Kim YY, Park KC, et al. (2008) Crif1 is a novel transcriptional coactivator of STAT3. EMBO J 27: 642-653. (Pubitemid 351273122)
30. Oh NS, Yoon SH, Lee WK, Choi JY, Min DS, et al. (2007) Phosphorylation of CKBBP2/CRIF1 by protein kinase CKII promotes cell proliferation. Gene 386: 147-153. (Pubitemid 44918240)
31. Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12: 676-684.
32. Möröy T, Geisen C (2004) Cyclin E. Int J Biochem Cell Biol 36: 1424-1439. (Pubitemid 38625823)
33. Morgan DO (1995) Principles of CDK regulation. Nature 374: 131-134.
34. Kleinberger-Doron N, Shelah N, Capone R, Gazit A, Levitzki A (1998) Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res 241: 340-351. (Pubitemid 28366560)
35. Wierød L, Rosseland CM, Lindeman B, Oksvold MP, Grøsvik H, et al. (2008) Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and Sphase entry in primary rat hepatocytes. Oncogene 27: 2763-2771. (Pubitemid 351581471)
36. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163.
37. DelSal G, Loda M, Pagano M (1996) Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog 7: 127-142. (Pubitemid 27238850)